




U.S. Department
of Transportation
**Federal Aviation
Administration**



800 Independence Ave., S.W.
Washington, D.C. 20591

DEC 10 1990

Plan Identification No. E-NM-00008-U
[D-NM-032]

Mr. Yasuo Sumida
Teijin Seiki America, Inc.
17770 N.E. 78th Place
Redmond, Washington 98052-4960

Dear Mr. Sumida:

I am pleased to inform you that your enclosed anti-drug plan has been approved by the Federal Aviation Administration (FAA). Under the terms of this approval, you are authorized to begin testing covered employees December 11, 1990. This approval is also contingent on your continuing association with the Workplace Systems, Inc. Consortium as specified in your plan. Should you terminate or modify the terms of your consortium membership, you must notify FAA, and submit an alternative plan for meeting the requirements of the drug testing program. Your plan has been issued the unique identification number shown above. Please be sure to include this number in any communication to the FAA regarding your program.

Federal Aviation Regulations require submission of semi-annual and annual reports to the FAA Office of Aviation Medicine. Initial reports should be submitted by August 15, 1991, and should cover the period from initial implementation of your program through June 30, 1991. A sample reporting format is enclosed. Reports may be submitted directly to FAA, or through your approved consortium depending on the terms of your membership.

Please feel free to contact this office if you have any questions regarding the FAA Anti-Drug Program.

Sincerely,

Diane J. Wood
Acting Manager, Drug Abatement Branch
Office of Aviation Medicine

Enclosures

cc: Workplace Systems, Inc. Consortium